356 related articles for article (PubMed ID: 10937355)
1. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
Jong MC; Havekes LM
Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
[TBL] [Abstract][Full Text] [Related]
4. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
[TBL] [Abstract][Full Text] [Related]
5. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
[TBL] [Abstract][Full Text] [Related]
6. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III.
Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC
Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516
[TBL] [Abstract][Full Text] [Related]
7. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism.
Shachter NS
Curr Opin Lipidol; 2001 Jun; 12(3):297-304. PubMed ID: 11353333
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
Ooi EM; Barrett PH; Chan DC; Watts GF
Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
[TBL] [Abstract][Full Text] [Related]
9. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations.
Al-Haideri M; Goldberg IJ; Galeano NF; Gleeson A; Vogel T; Gorecki M; Sturley SL; Deckelbaum RJ
Biochemistry; 1997 Oct; 36(42):12766-72. PubMed ID: 9335533
[TBL] [Abstract][Full Text] [Related]
11. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo.
Heeren J; Niemeier A; Merkel M; Beisiegel U
J Mol Med (Berl); 2002 Sep; 80(9):576-84. PubMed ID: 12226739
[TBL] [Abstract][Full Text] [Related]
12. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells.
Huard K; Bourgeois P; Rhainds D; Falstrault L; Cohn JS; Brissette L
Int J Biochem Cell Biol; 2005 Jun; 37(6):1308-18. PubMed ID: 15778093
[TBL] [Abstract][Full Text] [Related]
13. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
Ebara T; Ramakrishnan R; Steiner G; Shachter NS
J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
[TBL] [Abstract][Full Text] [Related]
14. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
[TBL] [Abstract][Full Text] [Related]
15. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
[TBL] [Abstract][Full Text] [Related]
16. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
Dinkel RE; Barrett PH; Demant T; Parhofer KG
Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.
Jong MC; Rensen PC; Dahlmans VE; van der Boom H; van Berkel TJ; Havekes LM
J Lipid Res; 2001 Oct; 42(10):1578-85. PubMed ID: 11590213
[TBL] [Abstract][Full Text] [Related]
18. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan DC; Chen MM; Ooi EM; Watts GF
Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.
Sehayek E; Eisenberg S
J Biol Chem; 1991 Sep; 266(27):18259-67. PubMed ID: 1917954
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
